We can always come for additional sectors in the future, depending on objectives and resourcing.
Cut out the middleman.
"In 2021, Medicare Part D covered more than 3,500 prescription drug products, with total gross spending of $216 billion, not accounting for rebates paid by drug manufacturers to pharmacy benefit managers (PBMs)."
https://www.kff.org/medicare/issue-brief/a-small-number-of-d...
From this post:
> Peter Maybarduk, the director of the Access to Medicines program at Public Citizen, a watchdog organization, who also testified at the hearing, hit back at the main pharmaceutical talking points along with Sanders. That included noting that the makers of the 10 drugs selected for the first round of Medicare price negotiation spent $10 billion more on self-enriching activities than R&D.
($200B/year buys a lot of manufacturing, distribution, admin, and whatever is left over for amortized and ongoing R&D)
The problem is that nobody actually knows or can predict what "meaningful work" is because drug discovery is a graveyard with a >90% death rate.
About 1.8M voters over the age of 55 die every year, we know how they vote. 4M young folks turn 18 every year, and we have a rough idea what their macro concerns are. Through the electorate death rate, progress is inevitable. This is not magic or miracles, simply systems thinking applied to demographics and political sciences.
Pharma is being challenged in this thread, the tax prep industry with the IRS developing their own tax filing system, FedNow challenging $100B credit card rails industry with cheap utility instant payments. Whose next? was my comment thesis. Important to not say things aren’t impossible when they’re being done. We’re just arguing trajectory and time horizon. Lots of paths to success.
This sounds like a terrible business environment. Are you thinking through the long term consequences of this?